Free Newsletter

  Email address:
   

Site Search

Chemizon Collaborates with Korean Research Institute

publication date: Feb 13, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Chemizon, a drug discovery CRO based in the US but with labs in Seoul and Beijing, will collaborate with the Korean Research Institute of Bioscience and Biotechnology (KRIBB) to commercialize KRIBB’s IP. To do this, the two entities will spin out a new biotech company. Chemizon said that its new Chemizon-Oakwood Bioventures private equity fund will be the lead investor in the new KRIBB company, currently given the working name “NuCo.” Chemizon-Oakwood Bioventures will build a management team and incubate the company. At the same time, Chemizon will use its integrated drug discovery platform to help convert KRIBB’s discoveries into small molecule therapeutics.

Stock Symbols: (NSDQ: ARRY) (KOSDAQ:010170)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...


Login

 

 
   
ChinaBio Events

October 24, 2008
Beijing, China

>> More details...

Partner Events
 
October 11-13, 2008
Dalian, China
 
U.S. FDA Inspections in China
October 15, 2008 
China
 
November 8, 2008
San Diego, CA
 
November 9-11, 2008
Shanghai, China
 
February 23-25, 2009
San Diego

>> More details...

Partners